Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Arrowhead Research (ARWR) PT Lowered to $5 at Jefferies Following Clinical Hold
November 10, 2016 7:54 AM ESTJefferies analyst Eun Yang reiterated a Hold rating and cut his price target on Arrowhead Research (NASDAQ: ARWR) to $5.00 (from $6.50) following clinical hold.
Yang commented, "FDA's decision to place a clinical hold on Heparc-2004 trial of ARC-520 based on death in... More
